首页> 外文期刊>Molecular BioSystems >Cardioprotective mechanism study of salvianic acid A sodium based on a proteome microarray approach and metabolomic profiling of rat serum after myocardial infarction
【24h】

Cardioprotective mechanism study of salvianic acid A sodium based on a proteome microarray approach and metabolomic profiling of rat serum after myocardial infarction

机译:基于蛋白质组芯片方法和心肌梗死后大鼠血清代谢组学分析的丹酚酸A钠的心脏保护机制研究

获取原文
获取原文并翻译 | 示例
       

摘要

Salvianic acid A sodium (SAAS), derived from a well-known herbal medicine Danshen (Salvia miltiorrhiza), is a new drug involved in phase I clinical trials in China for the treatment of coronary heart disease and stable angina pectoris. However, the direct binding protein(s) of SAAS are not understood and the broader cardioprotective effects as well as the underlying mechanisms remain to be further elucidated. In this study, Sprague-Dawley rats were subjected to left anterior descending artery ligation to investigate the cardioprotective effect of SAAS against myocardial infarction (MI). Moreover, a human proteome microarray was used to identify the direct binding proteins of SAAS, which was further verified by metabolomic profiling of rat serum after MI using an ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS) based approach. Our results demonstrated that SAAS significantly improved cardiac function and protected against MI-induced injury. In total, 370 proteins were identified to specifically bind SAAS and strikingly enriched in metabolic pathways. Rat serum metabolomic profiling identified 26 potential biomarkers including various glycerophospholipids (GPLs) and an array of fatty acids. Metabolic pathway analysis found increased phospholipid catabolism, sphingolipid metabolism and linoleic acid metabolism, decreased tryptophan metabolism, and impaired glycerophospholipid metabolism and primary bile acid biosynthesis in MI animals, while SAAS remarkably reversed these metabolic changes. SAAS may protect against myocardial infarction in rats by reversing multiple metabolic changes-induced by MI injury. Our findings will shed light on the cardioprotective mechanism of SAAS and aid its clinical use. Moreover, the SAAS-binding proteins identified by the proteome microarray are expected to be a valuable resource for its greater development.
机译:丹参酸A钠(SAAS)源自著名的草药丹参(Salvia miltiorrhiza),是一种新药,参与中国的一期临床试验,用于治疗冠心病和稳定型心绞痛。然而,尚不了解SAAS的直接结合蛋白,更广泛的心脏保护作用以及潜在的机制仍有待进一步阐明。在这项研究中,对Sprague-Dawley大鼠进行左前降支结扎,以研究SAAS对心肌梗塞(MI)的心脏保护作用。此外,使用人类蛋白质组芯片来鉴定SAAS的直接结合蛋白,并通过超高效液相色谱/四极杆飞行时间质谱(UPLC-QTOF-MS)对MI后大鼠血清的代谢组学谱进行了进一步验证。 MS)方法。我们的结果表明,SAAS可以显着改善心脏功能并防止MI引起的损伤。总共鉴定出370种蛋白质与SAAS特异性结合,并在代谢途径中显着富集。大鼠血清代谢组学分析确定了26种潜在的生物标志物,包括各种甘油磷脂(GPL)和一系列脂肪酸。代谢途径分析发现MI动物的磷脂分解代谢增加,鞘脂代谢和亚油酸代谢减少,色氨酸代谢减少,甘油磷脂代谢和主要胆汁酸生物合成受损,而SAAS显着逆转了这些代谢变化。 SAAS可能通过逆转MI损伤引起的多种代谢变化来预防大鼠心肌梗塞。我们的发现将阐明SAAS的心脏保护机制,并有助于其临床应用。此外,通过蛋白质组微阵列鉴定的SAAS结合蛋白有望成为其更大发展的宝贵资源。

著录项

  • 来源
    《Molecular BioSystems》 |2019年第4期|271-279|共9页
  • 作者单位

    Second Mil Med Univ Sch Pharm 325 Guohe Rd Shanghai 200433 Peoples R China;

    Second Mil Med Univ Sch Pharm 325 Guohe Rd Shanghai 200433 Peoples R China|Shanghai Univ Sch Med Shanghai 200444 Peoples R China;

    PLA 305 Hosp Dept Pharm Beijing 100017 Peoples R China;

    Second Mil Med Univ Sch Pharm 325 Guohe Rd Shanghai 200433 Peoples R China|Cent S Univ Xiangya Hosp 3 Changsha 410008 Hunan Peoples R China|Cent S Univ Inst Vasc Dis & Translat Med Changsha 410008 Hunan Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号